Cargando…
Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate
Targeted delivery of chemotherapeutic agents is a new approach for the treatment of cancer, which provides increased selectivity and decreased systemic toxicity. We have recently developed a promising drug delivery system, in which the anticancer drug daunorubicin (Dau) was attached via oxime bond t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981732/ https://www.ncbi.nlm.nih.gov/pubmed/24718594 http://dx.doi.org/10.1371/journal.pone.0094041 |
_version_ | 1782311098914963456 |
---|---|
author | Schreier, Verena Natalie Pethő, Lilla Orbán, Erika Marquardt, Andreas Petre, Brindusa Alina Mező, Gábor Manea, Marilena |
author_facet | Schreier, Verena Natalie Pethő, Lilla Orbán, Erika Marquardt, Andreas Petre, Brindusa Alina Mező, Gábor Manea, Marilena |
author_sort | Schreier, Verena Natalie |
collection | PubMed |
description | Targeted delivery of chemotherapeutic agents is a new approach for the treatment of cancer, which provides increased selectivity and decreased systemic toxicity. We have recently developed a promising drug delivery system, in which the anticancer drug daunorubicin (Dau) was attached via oxime bond to a gonadotropin-releasing hormone-III (GnRH-III) derivative used as a targeting moiety (Glp-His-Trp-Lys(Ac)-His-Asp-Trp-Lys(Dau = Aoa)-Pro-Gly-NH(2); Glp = pyroglutamic acid, Ac = acetyl; Aoa = aminooxyacetyl). This bioconjugate exerted in vitro cytostatic/cytotoxic effect on human breast, prostate and colon cancer cells, as well as significant in vivo tumor growth inhibitory effect on colon carcinoma bearing mice. In our previous studies, H-Lys(Dau = Aoa)-OH was identified as the smallest metabolite produced in the presence of rat liver lysosomal homogenate, which was able to bind to DNA in vitro. To get a deeper insight into the mechanism of action of the bioconjugate, changes in the protein expression profile of HT-29 human colon cancer cells after treatment with the bioconjugate or free daunorubicin were investigated by mass spectrometry-based proteomics. Our results indicate that several metabolism-related proteins, molecular chaperons and proteins involved in signaling are differently expressed after targeted chemotherapeutic treatment, leading to the conclusion that the bioconjugate exerts its cytotoxic action by interfering with multiple intracellular processes. |
format | Online Article Text |
id | pubmed-3981732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39817322014-04-11 Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate Schreier, Verena Natalie Pethő, Lilla Orbán, Erika Marquardt, Andreas Petre, Brindusa Alina Mező, Gábor Manea, Marilena PLoS One Research Article Targeted delivery of chemotherapeutic agents is a new approach for the treatment of cancer, which provides increased selectivity and decreased systemic toxicity. We have recently developed a promising drug delivery system, in which the anticancer drug daunorubicin (Dau) was attached via oxime bond to a gonadotropin-releasing hormone-III (GnRH-III) derivative used as a targeting moiety (Glp-His-Trp-Lys(Ac)-His-Asp-Trp-Lys(Dau = Aoa)-Pro-Gly-NH(2); Glp = pyroglutamic acid, Ac = acetyl; Aoa = aminooxyacetyl). This bioconjugate exerted in vitro cytostatic/cytotoxic effect on human breast, prostate and colon cancer cells, as well as significant in vivo tumor growth inhibitory effect on colon carcinoma bearing mice. In our previous studies, H-Lys(Dau = Aoa)-OH was identified as the smallest metabolite produced in the presence of rat liver lysosomal homogenate, which was able to bind to DNA in vitro. To get a deeper insight into the mechanism of action of the bioconjugate, changes in the protein expression profile of HT-29 human colon cancer cells after treatment with the bioconjugate or free daunorubicin were investigated by mass spectrometry-based proteomics. Our results indicate that several metabolism-related proteins, molecular chaperons and proteins involved in signaling are differently expressed after targeted chemotherapeutic treatment, leading to the conclusion that the bioconjugate exerts its cytotoxic action by interfering with multiple intracellular processes. Public Library of Science 2014-04-09 /pmc/articles/PMC3981732/ /pubmed/24718594 http://dx.doi.org/10.1371/journal.pone.0094041 Text en © 2014 Schreier et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Schreier, Verena Natalie Pethő, Lilla Orbán, Erika Marquardt, Andreas Petre, Brindusa Alina Mező, Gábor Manea, Marilena Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate |
title | Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate |
title_full | Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate |
title_fullStr | Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate |
title_full_unstemmed | Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate |
title_short | Protein Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic Daunorubicin-GnRH-III Derivative Bioconjugate |
title_sort | protein expression profile of ht-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-gnrh-iii derivative bioconjugate |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981732/ https://www.ncbi.nlm.nih.gov/pubmed/24718594 http://dx.doi.org/10.1371/journal.pone.0094041 |
work_keys_str_mv | AT schreierverenanatalie proteinexpressionprofileofht29humancoloncancercellsaftertreatmentwithacytotoxicdaunorubicingnrhiiiderivativebioconjugate AT petholilla proteinexpressionprofileofht29humancoloncancercellsaftertreatmentwithacytotoxicdaunorubicingnrhiiiderivativebioconjugate AT orbanerika proteinexpressionprofileofht29humancoloncancercellsaftertreatmentwithacytotoxicdaunorubicingnrhiiiderivativebioconjugate AT marquardtandreas proteinexpressionprofileofht29humancoloncancercellsaftertreatmentwithacytotoxicdaunorubicingnrhiiiderivativebioconjugate AT petrebrindusaalina proteinexpressionprofileofht29humancoloncancercellsaftertreatmentwithacytotoxicdaunorubicingnrhiiiderivativebioconjugate AT mezogabor proteinexpressionprofileofht29humancoloncancercellsaftertreatmentwithacytotoxicdaunorubicingnrhiiiderivativebioconjugate AT maneamarilena proteinexpressionprofileofht29humancoloncancercellsaftertreatmentwithacytotoxicdaunorubicingnrhiiiderivativebioconjugate |